Reuters logo
BRIEF-Kowa Pharmaceuticals enters agreement with CymaBay Therapeutics to license gout compound
January 3, 2017 / 9:43 PM / 9 months ago

BRIEF-Kowa Pharmaceuticals enters agreement with CymaBay Therapeutics to license gout compound

Jan 3 (Reuters) - Kowa Pharmaceuticals America Inc

* Kowa Pharmaceuticals America Inc announces agreement with CymaBay Therapeutics to license gout compound

* Kowa Pharmaceuticals America - will license product from CymaBay, which has completed a combined 17 phase 1 and phase 2 studies in over 1,100 subjects

* Kowa Pharmaceuticals America - CymaBay will receive pre-specified milestone and sales-related payments

* Kowa Pharmaceuticals America - under terms of agreement, co will manage Phase 3 clinical development program for arhalofenate

* Kowa Pharmaceuticals America - under terms of agreement, co will commercialize arhalofenate upon approval of arhalofenate in combination with febuxostat in U.S. Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below